ASBP News & Events

Aspire Biopharma Holdings is expanding its retail footprint with the launch of the BUZZ BOMB Convenience Store Pack. The lineup includes the newly designed six-count "Fruit Blast" package containing two each of the following flavors: Tropical Fruit, Mixed Berry, and Peach Mango, allowing for packaging options that fit changing habits.

Aspire Biopharma announced a strategic partnership with Microsize. Aspire has engaged Microsize to accelerate the development of a novel sublingual powder formulation of alprazolam, the active pharmaceutical ingredientI in the widely prescribed anti-anxiety medication Xanax.

Aspire Biopharma announced a "massive" expansion of its social media and digital marketing footprint for its wholly owned subsidiary, Buzz Bomb Caffeine Company. The company said, "The initiative follows a successful strategic rebranding and a high-profile sponsorship of professional ultra-marathoner Ashley Paulson, whose recent world-record performance catalyzed a significant increase in brand visibility and consumer acquisition. BUZZ BOMB-a caffeine supplement delivering a precise 50mg serving in convenient and flavorful stick packs-has seen its social media content surpass 400,000 views in a 48-hour period after the race. This digital momentum coincides with the brand's recent evolution, featuring a sleek modern website and science-forward packaging designed to appeal to high-performance athletes and everyday consumers alike. The brand's visibility reached a fever pitch at the 2026 Jackpot Ultra Running Festival. BUZZ BOMB Brand Ambassador Ashley Paulson set a new women's world record during the USATF 100-Mile Road Championship, winning the event by over two hours with a staggering time of 12:19:34. Competing in her signature pink ponytail and BUZZ BOMB gear, Paulson credited her use of BUZZ BOMB caffeine supplements for helping her maintain her 7:21 per mile pace throughout the 100-mile race. Ashley's accomplishments were highlighted in Runner's World and on the US Track and Field web sites. Runner's World featured an article about Ashley's record."

Aspire Biopharma Holdings received a notification letter from The Nasdaq Stock Market confirming that the Company has regained compliance with the minimum stockholders' equity threshold of $2.5M under Listing Rule 5550(b)(1). The Company announced on February 10, 2026 that it had received a letter from Nasdaq that the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Company is now in full compliance with all Nasdaq continued listing requirements and the Company's common stock will remain listed and traded on the Nasdaq Stock Market. Notwithstanding the compliance determination, the Company was also notified that it will remain subject to a "Panel Monitor," as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), for a period of one year from the date of the Nasdaq notice, through February 18, 2027. If, during the term of the Panel Monitor, the Company does not continue to remain in compliance with the $2.5M equity requirement, the Company will not be provided with the opportunity to submit a compliance plan for review by the Listing Qualifications Staff and must instead request a hearing before the Panel to address the deficiency, with such request staying any further action with respect to the Company's listing on Nasdaq pending completion of the hearing process.